Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation

Liver Transplantation

Volumn 14, Issue 5, 2008, Pages 647-650

  Soyama, Akihiko ^a   Eguchi, Susumu ^a   Takatsuki, Mitsuhisa ^a   Ichikawa, Tatsuki ^a   Moriuchi, Masako ^a   Moriuchi, Hiroyuki ^a   Nakamura, Tatsufumi ^a   Tajima, Yoshitsugu ^a   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BILIRUBIN; RIBAVIRIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CATHETERIZATION; CEREBROSPINAL FLUID ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; HEPATITIS C; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT INFECTION; SPINAL CORD INFECTION; TREATMENT DURATION; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GAIT DISORDERS, NEUROLOGIC; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PARAPARESIS, TROPICAL SPASTIC; STEROIDS; TACROLIMUS; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 43849100893     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21414     Document Type: Article

References (17)

1. Tajima K, Kuroishi T. Estimation of rate of incidence of ATL among ATLV (HTLV-1) carriers in Kyusyu, Japan. Jpn J Clin Oncol 1985;15:423-430.
2. Tajima K, Hinuma Y. Epidemiology of HTLV-I/II in Japan and the World. In: Takatsuki K, Hinuma Y, Yoshida M, eds. Gann monographs on cancer research. Vol. 39. Tokyo, Japan: Japanese Scientific Societies Press; 1992: 129-147.
3. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-7419.
4. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981;78:6476-6480.
5. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A. et al. HTLV-1 associated myelopathy, a new clinical entity. Lancet 1986;1:1031-1032.
6. Kawano N, Shimoda K, Ishikawa F, Taketomi A, Yoshizumi T, Shimoda S, et al. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 2006; 82:840-843.
7. Toro C, Rodes B, Poveda E, Soliano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003:75: 102-104.
8. Osame M, Igata A, Matsumoto M, Kohka M, Usuku K, Izumo S. HTLV-I-associated myelopathy (HAM) treatment trials. Retrospective survey and clinical and laboratory findings. Hematol Rev 1990;3:271-284.
9. Ijichi S, Izumo S, Eiraku N, Machigashira K, Kubota R, Nagai M, et al. An autoaggressive process against by-stander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med Hypotheses 1993;41: 542-547.
10. Nakazuka T, Umemiya-Okada T, Matsui T, Saida T, Nakao Y. FK506 and cyclosporin a regulate proliferation and proto-oncogene expression in HTLV-1-associated myelopathy/tropical-spastic-paraparesis-derived T cells. Int J Cancer 1993;54:348-354.
11. Nakagawa M, Nakahara K, Maruyama Y. Kawabata M, Higuchi I, Kubota H, et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol 1996;2:345-355.
12. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996;46:1016-1021.
13. Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N, et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-1-associated myelopathy/tropical spastic paraparesis. Infect Dis 2004;189:29-40.
14. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Morityoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998;4:586-593.
15. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007;19:61-66.
16. Aktipi KM, Ravaglia S, Ceroni M, Nemni R, Debiaggi M, Bastianello S, et al. Severe recurrent myelitis in patients with hepatitis C virus infection. Neurology 2007:68:468-469.
17. Imirizaldu JJ, Esteban JC, Axpe IR, Concha TP, Juanes FV, Susaeta IA, et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry 2003;74:1080-1084.